WINCANTON PLC - Director/PDMR Shareholding
- 27
WINCANTON PLC - Director/PDMR Shareholding
PR Newswire
London, January 20
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
a) | Name |
|
||||||
2 | Reason for the notification | |||||||
a) | Position/status |
|
||||||
b) | Initial notification/Amendment | Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Wincanton plc | ||||||
b) | LEI | 213800Z5WTW8QKOHWQ82 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
a) | Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of 10p each in Wincanton plc ISIN: GB0030329360 |
||||||
b) | Nature of the transaction | Shares purchased for the PDMRs listed above in respect of Partnership and Matching Shares, under the Wincanton plc approved Share Incentive Plan 2003 | ||||||
c) | Price(s) and volume(s) |
|
||||||
d) | Aggregated information | |||||||
-Aggregated volume |
|
|||||||
e) | Date of the transaction | 18 January 2021 | ||||||
f) | Place of the transaction | XLON |
For further information, please contact:
Lyn Colloff, Company Secretary Tel: 01249 710 000
PR Newswire
PR Newswire's news distribution, targeting, monitoring and marketing solutions help you connect and engage with target audiences across the globe.
Lastest news
- Shareholder Alert: Ademi LLP investigates whether HashiCorp Inc. has obtained a Fair Price in its transaction with IBM
- Marex Group plc Announces Pricing of Initial Public Offering
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- TransAlta Declares Dividends
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST